| Autor: |
Meng, Wei, Brigance, Robert, Mignone, James, Negash, Lidet, Zhao, Guohua, Ahmad, Saleem, Wang, Wei, Moore, Fang, Ye, Xiang-Yang, Sun, Jung-Hui, Mathur, Arvind, Li, Yi-Xin, Azzara, Anthony, Ma, Zhengping, Chu, Ching-Hsuen, Cullen, Mary Jane, Rooney, Suzanne, Harvey, Susan, Kopcho, Lisa, Abell, Lynn, O’Malley, Kevin, Keim, William, Dierks, Elizabeth A., Chang, Shu, Foster, Kimberly A., Harden, David, Dabros, Marta, Goti, Vineet, De Oliveira, Claudia, Krishna, Gopal, Pelleymounter, Mary Ann, Whaley, Jean, Robl, Jeffrey A., Cheng, Dong, Devasthale, Pratik |
| Zdroj: |
Journal of Medicinal Chemistry; September 2023, Vol. 66 Issue: 18 p13135-13147, 13p |
| Abstrakt: |
A series of dihydropyridinone (DHP) compounds was prepared and evaluated for MGAT2 activity. The efforts led to the identification of novel tetrazolones with potent MGAT2 inhibitory activity and favorable in vitroprofiles. Further tests of select analogues in mouse models revealed significant reduction in food intake and body weight. Subsequent studies in MGAT2 knockout mice with the lead candidate 12(BMS-986172) showed on-target- and mechanism-based pharmacology. Moreover, its favorable pharmacokinetic (PK) profile and the lack of species variability in the glucuronidation potential resulted in a greater confidence level in the projection of a low dose for achieving targeted efficacious exposures in humans. Consistent with these projections, PK data from a phase 1 trial confirmed that targeted efficacious exposures could be achieved at a low dose in humans, which supported compound 12as our second and potentially superior development candidate for the treatment of various metabolic disorders. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
